劉玟君 博士

研究副技師

中央研究院 生醫轉譯研究中心 

中央研究院 感染性疾病核心設施 計畫主持人 

Office: 轉譯中心 B547 (國家生技研究園區)

Office TEL: (02)7750-5815

Lab TEL: (02)7750-5500#2567

E-mail: wenchun0617@gate.sinica.edu.tw

 

研究簡介

劉玟君博士實驗室(感染性疾病核心設施，Infectious Disease Core facility, ID CORE)致力於傳染病和疫苗學兩大研究領域，針對重要新興/再興傳染病執行病原監測分析、鑑定、開發相應之動物模式及檢測平台，以及研發廣效型流感疫苗、COVID-19新冠病毒疫苗等，同時探討其相關致病機轉或免疫保護相關性(immuno-bridging)，相關成果亦發表於重要國際期刊(詳下列論文著作)。本核心設有BSL-2/ABSL-2及BSL-3/ABSL-3實驗室，著重於影響人類健康之重要傳染性疾病，包括季節性流感、禽流感、冠狀病毒(SARS-CoV-2)、季節性冠狀病毒、呼吸道融合病毒、腸病毒、登革熱以及其他常見人類傳染性疾病之研究。此外，本核心亦因應院內外學研機構及生技業者之需求，提供委託/合作研究及委託服務，內容包括合作研發、技術服務與BSL-2實驗室(含儀器設備)租用等。目前本核心已藉由現有開發技術平台及資源，協助數十個國內學研單位及廠商，執行病原培養、鑑定及疫苗/藥物效力評估(細胞及動物)等臨床前試驗，評估疫苗/藥物之保護效力以及研析其保護機轉。除一般小鼠動物模式外，我們亦積極開發、引進特殊小鼠品系以及建立倉鼠、雪貂動物模式，以縮短傳染病新藥、疫苗、保健食品以及其他傳染病防治相關產品之研發時程，並達到落實研究成果產品化、應用化之「化研為用」目標，期許能對人類健康做出實質貢獻，並促進國家生技產業之蓬勃發展。另外，當國內或國際出現疫情時，本核心亦積極參與國家疫病防疫體系，協助國家防疫，善盡社會責任。

 

學歷

          2015  國立清華大學生物科技研究所 博士

          2010  國立清華大學生物科技研究所 碩士

          2008   國立中興大學生命科學系 學士

 

經歷

        2025/02~迄今                  中央研究院生醫轉譯研究中心 研究副技師

        2025/01~迄今        中央研究院生醫轉譯研究中心生物安全管理委員會主席

        2024/01~迄今                  感染性疾病核心設施主持人

        2021/03~ 2025/02          中央研究院生醫轉譯研究中心 研究助技師

        2021/02~迄今        國防醫學院微生物及免疫學研究所 兼任助理教授

        2020/11~ 2021/02          中央研究院新興傳染病專題中心 博士後研究員

    2016-2020                       美國紐約西奈山伊坎醫學院微生物學研究所博士後研究員

專長

• 高防護實驗室軟硬體設計
• 新興傳染病/病毒學
• 疫苗學
• 免疫學
• 感染性疾病動物模式

 

榮譽事項

       2021 中央研究院新聘學術研究獎金

       2021 COVID-19 Pandemic Response Team, 美國紐約西奈山醫院

       2019 科技部未來科技獎

       2018 巴西São Paulo進階疫苗學研習全額獎學金

       2017 流感研究和監測卓越中心(CEIRS)培訓計劃獎 

       2017 國際疫苗協會(ISV)年會主席旅行獎金

       2016 科技部博士後千里馬計畫全額獎學金

       2015 國立清華大學生命科學院沈巨塵先生清華獎學金

       2012  HKU‐PASTEUR Immunology Course全額獎學金

       2011 國立清華大學生命科學院傑出論文獎

       2010 國立清華大學生命科學院校長獎學金

       2008 國立中興大學生命科學院畢業學士論文獎

 

論文著作

1. Hsieh HC, Chen CC, Liu WC, Wu SC. Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a subunit after primary mRNA vaccination in mice. Vaccine. 2024 (42):126448. PMID: 39413492.
2. Lee IJ, Lan YH, Wu PY, Wu YW, Chen YH, Tseng SC, Kuo TJ, Sun CP, Jan JT, Ma HH, Liao CC, Liang JJ, Ko HY, Chang CS, Liu WC, Ko YA, Chen YH, Sie ZL, Tsung SI, Lin YL, Wang IH, Tao MH. A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern. Emerg Microbes Infect. 2023 (12):2149353. PMID: 36395071.
3. Hsieh HC, Chen CC, Chou PH, Liu WC, Wu SC. Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit. Antiviral Res. 2023 (220):105752. PMID: 37949318.
4. Sun CP, Chiu CW, Wu PY, Tsung SI, Lee IJ, Hu CW, Hsu MF, Kuo TJ, Lan YH, Chen LY, Ng HY, Chung MJ, Liao HN, Tseng SC, Lo CH, Chen YJ, Liao CC, Chang CS, Liang JJ, Draczkowski P, Puri S, Chang YC, Huang JS, Chen CC, Kau JH, Chen YH, Liu WC, Wu HC, Danny Hsu ST, Wang IH, Tao MH. Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants. Mol Ther. 2023 (31):3322-3336. PMID: 37689971.
5. Ko HY, Li YT, Li YY, Chiang MT, Lee YL, Liu WC, Liao CC, Chang CS, Lin YL. Optimization and Improvement of qPCR Detection Sensitivity of SARS-CoV-2 in Saliva. Microbiol Spectr. 2023 (11):e0464022. PMID: 37097200.
6. Lee IJ, Sun CP, Wu PY, Lan YH, Wang IH, Liu WC, Yuan JP, Chang YW, Tseng SC, Tsung SI, Chou YC, Kumari M, Lin YS, Chen HF, Chen TY, Lin CC, Chiu CW, Hsieh CH, Chuang CY, Cheng CM, Lin HT, Chen WY, Hsu FF, Hong MH, Liao CC, Chang CS, Liang JJ, Ma HH, Chiang MT, Liao HN, Ko HY, Chen LY, Ko YA, Yu PY, Yang TJ, Chiang PC, Hsu ST, Lin YL, Lee CC, Wu HC, Tao MH. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. J Biomed Sci. 2022 (29):49. PMID: 35799178.
7. Nogales A^#, Steel J^#, Liu WC^#, Lowen AC, Rodriguez L, Chiem K, Cox A, García-Sastre A, Albrecht RA, Dewhurst S, Martínez-Sobrido L. Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine. Microbiol Spectr. 2022 (10):e0007822. PMID: 35583364. (#: Co-first author)
8. Peña N, Zhang W, Watkins C, Halucha M, Alshammary H, Hernandez MM, Liu WC, Albrecht RA, Garcia-Sastre A, Simon V, Katanski C, Pan T. Profiling Selective Packaging of Host RNA and Viral RNA Modification in SARS-CoV-2 Viral Preparations. Front Cell Dev Biol. 2022 (10):768356. PMID: 35186917.
9. Muthusamy S, Jan HM, Hsieh MY, Mondal S, Liu WC, Ko YA, Yang WY, Mong KT, Chen GC, Lin CH. Enhanced enzymatic production of cholesteryl 6'-acylglucoside impairs lysosomal degradation for the intracellular survival of Helicobacter pylori. J Biomed Sci. 2021 (28):72. PMID: 34706729.
10. Horiuchi S, Wu H, Liu WC, Schmitt N, Provot J, Liu Y, Bentebibel SE, Albrecht RA, Schotsaert M, Forst CV, Zhang B, Ueno H. Tox2 is required for the maintenance of GC TFH cells and the generation of memory TFH cells. Sci Adv. 2021 (7): eabj1249. PMID: 34623911.
11. Sindelar M, Stancliffe E, Schwaiger-Haber M, Anbukumar DS, Adkins-Travis K, Goss CW, O'Halloran JA, Mudd PA, Liu WC, Albrecht RA, García-Sastre A, Shriver LP, Patti GJ. Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity. Cell Rep Med. 2021 (2):100369. PMID: 34308390.
12. Sun CP, Jan JT, Wang IH, Ma HH, Ko HY, Wu PY, Kuo TJ, Liao HN, Lan YH, Sie ZL, Chen YH, Ko YA, Liao CC, Chen LY, Lee IJ, Tsung SI, Lai YJ, Chiang MT, Liang JJ, Liu WC, Wang JR, Yuan JP, Lin YS, Tsai YC, Hsieh SL, Li CW, Wu HC, Ko TM, Lin YL, Tao MH. Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. PLoS Pathog. 2021 (17):e1009758. PMID: 34379705.
13. Bryce C, Grimes Z, Pujadas E, Ahuja S, Beasley MB, Albrecht R, Hernandez T, Stock A, Zhao Z, AlRasheed MR, Chen J, Li L, Wang D, Corben A, Haines GK 3rd, Westra WH, Umphlett M, Gordon RE, Reidy J, Petersen B, Salem F, Fiel MI, El Jamal SM, Tsankova NM, Houldsworth J, Mussa Z, Veremis B, Sordillo E, Gitman MR, Nowak M, Brody R, Harpaz N, Merad M, Gnjatic S, Liu WC, Schotsaert M, Miorin L, Aydillo Gomez TA, Ramos-Lopez I, Garcia-Sastre A, Donnelly R, Seigler P, Keys C, Cameron J, Moultrie I, Washington KL, Treatman J, Sebra R, Jhang J, Firpo A, Lednicky J, Paniz-Mondolfi A, Cordon-Cardo C, Fowkes ME. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol. 2021 (34):1456-1467. PMID: 33795830.
14. El Jamal SM, Pujadas E, Ramos I, Bryce C, Grimes ZM, Amanat F, Tsankova NM, Mussa Z, Olson S, Salem F, Miorin L, Aydillo T, Schotsaert M, Albrecht RA, Liu WC, Marjanovic N, Francoeur N, Sebra R, Sealfon SC, García-Sastre A, Fowkes M, Cordon-Cardo C, Westra WH. Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. Hum Pathol. 2021 (114):110-119. PMID: 33961839.
15. Si L, Bai H, Rodas M, Cao W, Oh CY, Jiang A, Moller R, Hoagland D, Oishi K, Horiuchi S, Uhl S, Blanco-Melo D, Albrecht RA, Liu WC, Jordan T, Nilsson-Payant BE, Golynker I, Frere J, Logue J, Haupt R, McGrath M, Weston S, Zhang T, Plebani R, Soong M, Nurani A, Kim SM, Zhu DY, Benam KH, Goyal G, Gilpin SE, Prantil-Baun R, Gygi SP, Powers RK, Carlson KE, Frieman M, tenOever BR, Ingber DE. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nat Biomed Eng. 2021(5):815-829. PMID: 33941899.
16. Ho JSY, Mok BW, Campisi L, Jordan T, Yildiz S, Parameswaran S, Wayman JA, Gaudreault NN, Meekins DA, Indran SV, Morozov I, Trujillo JD, Fstkchyan YS, Rathnasinghe R, Zhu Z, Zheng S, Zhao N, White K, Ray-Jones H, Malysheva V, Thiecke MJ, Lau SY, Liu H, Zhang AJ, Lee AC, Liu WC, Jangra S, Escalera A, Aydillo T, Melo BS, Guccione E, Sebra R, Shum E, Bakker J, Kaufman DA, Moreira AL, Carossino M, Balasuriya UBR, Byun M, Albrecht RA, Schotsaert M, Garcia-Sastre A, Chanda SK, Miraldi ER, Jeyasekharan AD, TenOever BR, Spivakov M, Weirauch MT, Heinz S, Chen H, Benner C, Richt JA, Marazzi I. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell. 2021 (184):2618-2632.e17. PMID: 33836156.
17. Liu WC, Nachbagauer R, Stadlbauer D, Strohmeier S, Solórzano A, Berlanda-Scorza F, Innis BL, García-Sastre A, Palese P, Krammer F, Albrecht RA. Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model. Vaccines (Basel). 2021 (9). PMID: 33440898. (First author)
18. Sun W, McCroskery S, Liu WC, Leist SR, Liu Y, Albrecht RA, Slamanig S, Oliva J, Amanat F, Schäfer A, Dinnon KH 3rd, Innis BL, García-Sastre A, Krammer F, Baric RS, Palese P. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines (Basel). 2020 (8). PMID: 33348607.
19. Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, Burgstaller-Muehlbacher S, De Jesus PD, Teriete P, Hull MV, Chang MW, Chan JF, Cao J, Poon VK, Herbert KM, Cheng K, Nguyen TH, Rubanov A, Pu Y, Nguyen C, Choi A, Rathnasinghe R, Schotsaert M, Miorin L, Dejosez M, Zwaka TP, Sit KY, Martinez-Sobrido L, Liu WC, White KM, Chapman ME, Lendy EK, Glynne RJ, Albrecht R, Ruppin E, Mesecar AD, Johnson JR, Benner C, Sun R, Schultz PG, Su AI, García-Sastre A, Chatterjee AK, Yuen KY, Chanda SK. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020 (586):113-119. PMID: 32707573.
20. Muñoz-Fontela C, Dowling WE, Funnell SGP, Gsell PS, Riveros-Balta AX, Albrecht RA, Andersen H, Baric RS, Carroll MW, Cavaleri M, Qin C, Crozier I, Dallmeier K, de Waal L, de Wit E, Delang L, Dohm E, Duprex WP, Falzarano D, Finch CL, Frieman MB, Graham BS, Gralinski LE, Guilfoyle K, Haagmans BL, Hamilton GA, Hartman AL, Herfst S, Kaptein SJF, Klimstra WB, Knezevic I, Krause PR, Kuhn JH, Le Grand R, Lewis MG, Liu WC, Maisonnasse P, McElroy AK, Munster V, Oreshkova N, Rasmussen AL, Rocha-Pereira J, Rockx B, Rodríguez E, Rogers TF, Salguero FJ, Schotsaert M, Stittelaar KJ, Thibaut HJ, Tseng CT, Vergara-Alert J, Beer M, Brasel T, Chan JFW, García-Sastre A, Neyts J, Perlman S, Reed DS, Richt JA, Roy CJ, Segalés J, Vasan SS, Henao-Restrepo AM, Barouch DH. Animal models for COVID-19. Nature. 2020 (586):509-515. Review. PMID: 32967005.
21. Amanat F, White KM, Miorin L, Strohmeier S, McMahon M, Meade P, Liu WC, Albrecht RA, Simon V, Martinez-Sobrido L, Moran T, García-Sastre A, Krammer F. An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Curr Protoc Microbiol. 2020 (58):e108. PMID: 32585083.
22. Blanco-Melo D*, Nilsson-Payant BE*, Liu WC*, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020 May 28;181(5):1036-1045.e9. PMID: 32416070. (*Co-first author)
23. Rodriguez-Frandsen A, Martin-Sancho L, Gounder AP, Chang MW, Liu WC, De Jesus PD, von Recum-Knepper J, Dutra MS, Huffmaster NJ, Chavarria M, Mena I, Riva L, Nguyen CB, Dobariya S, Herbert KM, Benner C, Albrecht RA, García-Sastre A, Chanda SK. Viral Determinants in H5N1 Influenza A Virus Enable Productive Infection of HeLa Cells. J Virol. 2020 Jan 31;94(4). PMID: 31776276.
24. Chen TH, Liu WC, Chen IC, Liu CC, Huang MH, Jan JT, Wu SC. Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development. Vaccine. 2019 Nov 8;37(47):6933-6941. PMID: 31383491.
25. McMahon M, Asthagiri Arunkumar G, Liu WC, Stadlbauer D, Albrecht RA, Pavot V, Aramouni M, Lambe T, Gilbert SC, Krammer F. Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge. Front Immunol. 2019. 10:2005. PMID: 31497029.
26. Liu WC, Nachbagauer R, Stadlbauer D, Solórzano A, Berlanda-Scorza F, García-Sastre A, Palese P, Krammer F, Albrecht RA. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model. Front Immunol. 2019; 10:756. PMID: 31105689.
27. Chen TH, Liu WC, Lin CY, Liu CC, Jan JT, Spearman M, Butler M, Wu SC. Glycan-masking hemagglutinin antigens from stable CHO cell clones for H5N1 avian influenza vaccine development. Biotechnol Bioeng. 2019 Mar;116(3):598-609. PMID: 30080931.
28. Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, Albrecht RA, Bouvier NM, Simon V, Nachbagauer R, Krammer F, Palese P. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. J Clin Invest. 2018 Nov 1;128(11):4992-4996. PMID: 30188868.
29. Albrecht RA, Liu WC, Sant AJ, Tompkins SM, Pekosz A, Meliopoulos V, Cherry S, Thomas PG, Schultz-Cherry S. Moving Forward: Recent Developments for the Ferret Biomedical Research Model. mBio. 2018 Jul 17;9(4). PMID: 30018107.
30. DiPiazza AT, Richards KA, Liu WC, Albrecht RA, Sant AJ. Analyses of Cellular Immune Responses in Ferrets Following Influenza Virus Infection. Methods Mol Biol. 2018;1836:513-530. PMID: 30151589.
31. Liu WC, Nachbagauer R, Krammer F, Albrecht RA. Assessment of Influenza Virus Hemagglutinin Stalk-Specific Antibody Responses. Methods Mol Biol. 2018; 1836:487-511. PMID: 30151588.
32. Nachbagauer R, Liu WC, Choi A, Wohlbold TJ, Atlas T, Rajendran M, Solórzano A, Berlanda-Scorza F, García-Sastre A, Palese P, Albrecht RA, Krammer F. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ Vaccines. 2017; 2:26. PMID: 29263881.
33. Liu WC, Jan JT, Huang YJ, Chen TH, Wu SC. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design. J Virol. 2016 Oct 1;90(19):8496-508. PMID: 27440889.
34. Liu WC, Liu YY, Chen TH, Liu CC, Jan JT, Wu SC. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design. Antiviral Res. 2016 Sep;133:110-8. PubMed PMID: 27491439.
35. Liu WC, Lin YL, Spearman M, Cheng PY, Butler M, Wu SC. Influenza Virus Hemagglutinin Glycoproteins with Different N-Glycan Patterns Activate Dendritic Cells In Vitro. J Virol. 2016 Jul 1;90(13):6085-6096. PMID: 27099319.
36. Li TW, Cheng SF, Tseng YT, Yang YC, Liu WC, Wang SC, Chou MJ, Lin YJ, Wang Y, Hsiao PW, Wu SC, Chang DK. Development of single-chain variable fragments (scFv) against influenza virus targeting hemagglutinin subunit 2 (HA2). Arch Virol. 2016 Jan;161(1):19-31. PMID: 26446888.
37. Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses. J Virol. 2015 Jul;89(14):7224-34. PMID: 25948745.
38. Lin SC, Liu WC, Jan JT, Wu SC. Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS One. 2014;9(3):e92822. PMID: 24671139.
39. Lin SC, Liu WC, Lin YF, Huang YH, Liu JH, Wu SC. Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses. Biotechnol J. 2013 Nov;8(11):1315-22. PMID: 23813782.
40. Lin LC, Hsu SL, Wu CL, Liu WC, Hsueh CM. Peroxisome proliferator-activated receptor γ (PPARγ) plays a critical role in the development of TGFβ resistance of H460 cell. Cell Signal. 2011 Oct;23(10):1640-50. PMID: 21664967.
41. Wei HJ, Chang W, Lin SC, Liu WC, Chang DK, Chong P, Wu SC. Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. Vaccine. 2011 Sep 22;29(41):7163-72. PMID: 21651946.
42. Liu WC, Lin SC, Yu YL, Chu CL, Wu SC. Dendritic cell activation by recombinant hemagglutinin proteins of H1N1 and H5N1 influenza A viruses. J Virol. 2010 Nov;84(22):12011-7. PMID: 20844030.

 

專利

1. 吳夙欽、劉玟君、黃韻儒『去醣基化之血球凝集素蛋白及其製備方法』“Deglycosylated hemagglutinin and manufacture thereof” (中華民國專利發明第I 488863號，專利權期間2015-6-21 至 2033-12-26)。
2. Wu SC, Liu WC, Huang YJ. Deglycosylated hemagglutinin and manufacture thereof (US Patent 9,644,008 B2, 2017-05-09 to 2034-05-18)
3. 吳夙欽、劉玟君、林佳瑩『重組神經胺酸酶蛋白及其應用』“Recombinant neuraminidase and uses thereof” (中華民國專利發明第I 588260號，專利權期間2017-06-21 至 2034-09-03)。
4. Wu SC, Liu WC, Lin CY. Recombinant neuraminidase and uses thereof (US Patent 9,688,965 B2, 2017-06-27 to 2035-05-20)
5. 吳夙欽、劉玟君、林佳瑩『重組神經胺酸酶蛋白及其應用』“Recombinant neuraminidase and uses thereof” (中國專利申請案第201510555504.4號)。